Maria Silvoniemi1, Tuula Vasankari2, Eliisa Löyttyniemi3, Mauno Valtonen4, Eeva Salminen5. 1. Department of Respiratory Medicine, Turku University Hospital, Turku, Finland Department of Respiratory Medicine, University of Turku, Turku, Finland marber@utu.fi. 2. Finnish Lung Health Association (Filha ry), Helsinki, Finland. 3. Institute of Clinical Medicine, Biostatistics, University of Turku, Turku, Finland. 4. Department of Radiology, Turku University Hospital, Turku, Finland. 5. Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland Department of Oncology and Radiotherapy, University of Turku, Turku, Finland.
Abstract
AIM: This study assessed the symptoms and health-related quality of life (HRQOL) of patients with advanced non-small cell lung cancer (NSCLC) and examined the symptom-associated characteristics. PATIENTS AND METHODS: The symptoms of 122 patients with NSCLC scheduled for chemotherapy before starting treatment were surveyed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire and Edmonton Symptom Assessment Scale (ESAS). RESULTS: The most prevalent symptoms were coughing (EORTC score 41.7), dyspnea (33.9), fatigue (31.9), insomnia (30.3) and pain (21.8). The mean EORTC score for global QoL was 56.9 (SD=23.5). Physical, cognitive and emotional functioning, insomnia, diarrhea, and dyspnea had a significant influence on the HRQOL (p<0.05). ESAS assessment correlated with these results and thus was an easy-to-use tool for symptom assessment (correlation coefficient range=0.546-0.865, p<0.0001 for all symptoms). CONCLUSION: Patients with advanced NSCLC suffer from multiple symptoms influencing HRQOL. ESAS provides a symptom assessment tool that is as reliable as but simpler to use than the EORTC questionnaire. Copyright
AIM: This study assessed the symptoms and health-related quality of life (HRQOL) of patients with advanced non-small cell lung cancer (NSCLC) and examined the symptom-associated characteristics. PATIENTS AND METHODS: The symptoms of 122 patients with NSCLC scheduled for chemotherapy before starting treatment were surveyed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire and Edmonton Symptom Assessment Scale (ESAS). RESULTS: The most prevalent symptoms were coughing (EORTC score 41.7), dyspnea (33.9), fatigue (31.9), insomnia (30.3) and pain (21.8). The mean EORTC score for global QoL was 56.9 (SD=23.5). Physical, cognitive and emotional functioning, insomnia, diarrhea, and dyspnea had a significant influence on the HRQOL (p<0.05). ESAS assessment correlated with these results and thus was an easy-to-use tool for symptom assessment (correlation coefficient range=0.546-0.865, p<0.0001 for all symptoms). CONCLUSION:Patients with advanced NSCLC suffer from multiple symptoms influencing HRQOL. ESAS provides a symptom assessment tool that is as reliable as but simpler to use than the EORTC questionnaire. Copyright
Authors: Ronica Nanda; David Boulware; Rachid Baz; Diane Portman; H Michael Yu; Heather Jim; Peter A S Johnstone Journal: Acta Oncol Date: 2020-06-04 Impact factor: 4.089
Authors: Melisa L Wong; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Fay Wright; Marilyn Hammer; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-05-19 Impact factor: 3.612
Authors: Grace E Dean; Patricia Ziegler; Hongbin Chen; Lynn M Steinbrenner; Suzanne S Dickerson Journal: Support Care Cancer Date: 2018-10-15 Impact factor: 3.603
Authors: Melisa L Wong; Steven M Paul; Bruce A Cooper; Laura B Dunn; Marilyn J Hammer; Yvette P Conley; Fay Wright; Jon D Levine; Louise C Walter; Frances Cartwright; Christine Miaskowski Journal: Support Care Cancer Date: 2017-02-03 Impact factor: 3.603
Authors: M N Yogananda; Valliappan Muthu; Kuruswamy Thurai Prasad; Adarsh Kohli; Digambar Behera; Navneet Singh Journal: Support Care Cancer Date: 2017-10-12 Impact factor: 3.603